Alto Neuroscience, Inc.
ANRO
$24.63
$0.100.41%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.06M | 4.43M | 5.56M | 5.70M | 6.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.06M | 14.95M | 18.68M | 15.68M | 17.00M |
| Operating Income | -17.06M | -14.95M | -18.68M | -15.68M | -17.00M |
| Income Before Tax | -16.18M | -14.18M | -17.71M | -15.17M | -15.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.18M | -14.18M | -17.71M | -15.17M | -15.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.18M | -14.18M | -17.71M | -15.17M | -15.20M |
| EBIT | -17.06M | -14.95M | -18.68M | -15.68M | -17.00M |
| EBITDA | -16.90M | -14.79M | -18.51M | -15.51M | -16.83M |
| EPS Basic | -0.47 | -0.52 | -0.65 | -0.56 | -0.57 |
| Normalized Basic EPS | -0.30 | -0.33 | -0.41 | -0.33 | -0.35 |
| EPS Diluted | -0.47 | -0.52 | -0.65 | -0.56 | -0.57 |
| Normalized Diluted EPS | -0.30 | -0.33 | -0.41 | -0.33 | -0.35 |
| Average Basic Shares Outstanding | 34.18M | 27.10M | 27.07M | 27.05M | 26.77M |
| Average Diluted Shares Outstanding | 34.18M | 27.10M | 27.07M | 27.05M | 26.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |